## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.97 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($181.24)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. BD Showcases Innovation in Connected Medication Management at ASHP Midyear Clinical Meeting**
- Source: BD Newsroom | 20251208T181516 | Bullish | Relevance: 99%
-  BD (Becton, Dickinson and Company) is presenting its latest advancements in connected medication management technology at the ASHP 2025 Midyear Clinical Meeting, featuring solutions like the next-generation BD Pyxis Pro Dispensing Solution and the AI-powered BD Incada Connected Care Platform. The company is also introducing the high-speed BD Rowa Vmax dispensing robot to the U.S. market and announcing a new partnership with Marble AI and Terso Solutions for RFID-enabled central pharmacy inventory management. These innovations aim to enhance safety, efficiency, and decision-making for clinicians through integrated technology.

**2. Is Becton Dickinson (BDX) Quietly Reframing Its Moat Around Everyday Hospital Safety Workflows?**
- Source: Simply Wall Street | 20251207T124441 | Somewhat-Bullish | Relevance: 99%
-  Becton Dickinson (BDX) is enhancing its position in hospital safety workflows through a new collaboration with ChemoGLO, integrating rapid hazardous drug testing with detailed lab analysis. This move aligns with BD's broader strategy of combining its installed base of medical consumables with innovation, including investments in Biosciences tools despite an upcoming segment separation. The company projects significant revenue and earnings growth, though investors should consider execution risks associated with the separation and varying fair value estimates within the investment community.

**3. Is Becton Dickinson (BDX) Quietly Reframing Its Moat Around Everyday Hospital Safety Workflows?**
- Source: Simply Wall Street | 20251207T130720 | Somewhat-Bullish | Relevance: 99%
-  Becton Dickinson (BD) recently announced a collaboration with ChemoGLO, integrating BD’s rapid hazardous drug tests with ChemoGLO’s lab analysis to improve hospital staff safety. This move aligns with BD’s strategy to embed its safety technologies deeper into hospital workflows and supports its "reset-and-separation" investment narrative. While the company focuses on innovation and a complex Biosciences and Diagnostics separation, investors should consider execution risks and various fair value estimates.

**4. Jump Financial LLC Raises Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251208T114458 | Somewhat-Bullish | Relevance: 99%
-  Jump Financial LLC significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 4,548.6% in the second quarter, bringing its total holdings to 65,173 shares valued at $11,226,000. Other institutional investors also adjusted their positions, and the company recently declared a quarterly dividend of $1.05 per share. Analysts generally hold a "Hold" rating on BDX with a consensus price target of $204.45.

**5. Natixis Has $10.33 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T130752 | Neutral | Relevance: 99%
- Natixis reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.9% in Q2, ending with 59,997 shares valued at $10.33 million. Despite this, institutional investors collectively own about 86.97% of the medical instruments supplier's stock. Becton, Dickinson recently increased its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20 and a yield of 2.2%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.1B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 11.9 |
| Current P/E | 12.6 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.2% to -3.7% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.71% (CS: 28) | Weak |
| RSI_14 | 47.5 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 0.989x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $188.82
- **Stop Loss:** $181.24 (4.0% risk)
- **Target:** $203.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $7,363.98
- **Portfolio %:** 7.36%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*